Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23719173 | 0.88 | CPB1 (0.43) | KMT2AMEN1NPC1CASP3RAB9A | |
| SCHEMBL23719175 | 0.84 | NPC1 (0.54) | KMT2AMEN1NPC1CASP3RAB9A | |
| SCHEMBL4107205 | 0.80 | TRPV1 (0.72) | KMT2AMEN1NPC1CASP3RAB9A | |
| SCHEMBL22828685 | 0.80 | MAPT (0.54) | KMT2AMEN1NPC1CASP3RAB9A | |
| SCHEMBL22828678 | 0.79 | KMT2A (0.58) | KMT2AMEN1NPC1CASP3RAB9A | |
| SCHEMBL15094124 | 0.77 | CA12 (0.74) | KMT2AMEN1NPC1CASP3RAB9A | |
| SCHEMBL27567730 | 0.73 | HSD17B10 (0.53) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL4117293 | 0.73 | CA12 (0.68) | KMT2AMEN1NPC1CASP3RAB9A | |
| SCHEMBL1519009 | 0.73 | MEN1 (0.56) | KMT2AMEN1NPC1CASP3RAB9A | |
| SCHEMBL15093703 | 0.72 | CA12 (0.73) | KMT2AMEN1NPC1CASP3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2021-08-05 | — | — | US | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | KMT2A 3772/4885MEN1 2199/4885NPC1 859/4885 |
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | KMT2A 4188/4885MEN1 1142/4885NPC1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.